Anteris Technologies

@DeviceTalks Minnesota is just around the corner! We’re pleased to share that Anteris CEO Wayne Paterson will take the stage on Monday, May 4 at 10:30 a.m. We look forward to an engaging discussion about the next generation of heart valve technology.

🔗 minnesota.devicetalks.com

#DeviceTalksMinnesota #MedTech #HeartValves #TAVR #TAVI

Today on Heart Valve Disease Awareness Day, we’re joining the global effort to shine a light on a condition that affects millions—often without symptoms. Heart valve disease, including conditions like aortic stenosis, can progress silently, making awareness and early detection essential for better outcomes. In this video, our Chief Medical Officer Christopher Meduri explains aortic stenosis symptoms and treatment options. For more information on symptoms or treatment, speak with your doctor.

This day is a reminder to:

✔️ Know the signs—fatigue, breathlessness, chest pain, dizziness
✔️ Encourage loved ones to get regular heart check-ups
✔️ Support continued research and innovation in cardiovascular health

Anteris remains dedicated to advancing outcomes for aortic stenosis patients and increasing understanding of this serious condition.

#HeartValveDiseaseAwarenessDay #HeartHealth #AorticStenosis #CardiovascularCare #HeartMonth

📢 Just published!

New data presented by Dr. Pankaj Garg at EAPCI Summit 2026 and simultaneously published in European Heart Journal demonstrated that the biomimetic DurAVR® Transcatheter Heart Valve, with its native-shaped leaflet geometry, restored native-like flow in patients with severe, symptomatic aortic stenosis. The post-DurAVR® THV aortic flow was comparable to that seen in age-, sex-, and hemodynamic-matched controls without aortic valve disease. The 4D CMR study evaluated 60 patients with severe AS pre-intervention and 6-months post-DurAVR® THV and compared aortic flow and LV mass to 35 matched controls, revealing:

✅ Significant reduction in flow displacement and flow reversal ratio post-DurAVR® THV vs. severe AS

✅ Post-DurAVR THV flow displacement comparable to matched healthy controls

✅ Significant LV mass reduction post-DurAVR, with LV mass returning to levels comparable to matched healthy controls

At Anteris, our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Together with our physician partners, we are working to advance valve science and outcomes for patients suffering from aortic stenosis. The currently enrolling PARADIGM Trial, with its imaging sub-study, has the potential to help uncover the clinical implications of restoring physiologic flow.

Read the full paper:➡️ academic.oup.com/ehjvshd/advanc…

#EAPCI26 #TAVR #TAVI #AorticStenosis #Biomimetic #LaminarFlow

DurAVR® THV is intended for INVESTIGATIONAL USE ONLY. Not available for commercial use or sale worldwide. Design and performance characteristics subject to clinical investigation and regulatory review. Potential contraindications, hazards, or adverse effects subject to clinical investigation and regulatory review. These materials are intended to notify clinical investigators.
CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.
EU: For Investigational use only. Not CE marked.

📢 Company Update! Anteris has completed combined $320M capital raises, including $230M from a public offering and $90M from a strategic investment from @Medtronic. These combined proceeds enable Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform the treatment of aortic stenosis.

“This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company. It also provides strong validation of our program from the capital markets and a major strategic innovator,” said Wayne Paterson, Anteris Vice Chairman and CEO.

Anteris and Medtronic are aligned around the belief that reshaping the Transcatheter Aortic Valve Replacement (TAVR) market requires advancing clinical science and valve design while maintaining rigorous standards for durability, hemodynamics, and long‑term patient outcomes.

Read the full press release to learn more: anteristech.com/investors/pres…

#TAVR #TAVI #AorticStenosis #PARADIGMtrial #MedTech

Hear perspectives from Prof. Ole De Backer and Prof. Nicolas Van Mieghem about the recent DurAVR® THV data and the PARADIGM Trial in this 2-part discussion series.

➡️ Part 1 highlights the PARADIGM trial—the first all-comers, head-to-head TAVI trial and the first TAVI trial designed to evaluate post-procedure blood flow patterns using cardiac MRI. With participation from 80 centers across the US, Canada, and Europe, recent FDA IDE approval, and first enrollments already completed in Denmark in October, the PARADIGM Trial is expected to enroll quickly, and the data gathered will be used to support future commercial approval of the DurAVR® valve for patients across all risk categories.
📽️ Watch Part 1: youtu.be/55R3Br-Ws6w?si…

➡️ Part 2 focuses on Prof. De Backer’s presentation of 30-day outcomes from 100 small annuli DurAVR® THV patients, providing early insights into clinical performance. DurAVR® THV demonstrated a favorable hemodynamic profile at 30 days, including 97% freedom from moderate or greater patient-prosthesis mismatch (PPM).(1)
📽️ Watch Part 2: youtu.be/UU6uhlsryRw?si…

(1) De Backer O. Oral Presentation at: PCR London Valves; Nov 2025; London, UK.

#TAVI #TAVR #AorticStenosis #PARADIGMtrial #MovingtheConversationForward
DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: For clinical investigations only.
US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.